Lexeo Therapeutics Inc. C...

NASDAQ: LXEO · Real-Time Price · USD
4.56
-0.23 (-4.80%)
At close: Aug 15, 2025, 12:37 PM

Lexeo Therapeutics Common Stock Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a 654K 1.66M
Cost of Revenue
n/a 1.84M 1.15M 13.4K
Gross Profit
n/a -1.84M -491K 1.64M
Operating Income
-105.77M -68.51M -60.51M -50.64M
Interest Income
7.56M 2.87M 1.32M 15K
Pretax Income
-98.33M -66.39M -59.28M -50.62M
Net Income
-98.33M -66.39M -59.28M -50.62M
Selling & General & Admin
31.68M 13.54M 12M 7.16M
Research & Development
74.09M 53.13M 49.16M 45.12M
Other Expenses
n/a n/a -2K n/a
Operating Expenses
105.77M 66.67M 61.16M 52.29M
Interest Expense
114K 205K 91K n/a
Selling & Marketing Expenses
n/a -1.84M n/a -13.38K
Cost & Expenses
n/a 68.51M 61.16M 52.29M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
31.79M 26.65M 25.17M 25.17M
Shares Outstanding (Diluted)
31.79M 26.65M 25.17M 25.17M
EPS (Basic)
-3.09 -2.49 -2.36 -2.01
EPS (Diluted)
-3.09 -2.49 -2.4 -2.01
EBITDA
-96.22M -66.67M -58.04M -50.62M
EBIT
-98.47M -66.19M -59.19M -50.62M
Depreciation & Amortization
n/a 1.84M 1.15M 13K